Inve India ▾

Gem Aromatics share price & results

Gem Aromatics Limited· Chemicals· Commodities

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Indian manufacturer and exporter of essential oils, aroma chemicals and specialty derivatives across Mint, Clove, Phenol and Citral chemistry platforms.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue98.9 ₹ crore+12.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin3.3 %−13.6 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-7.9 ₹ crore−198.6% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity-3.94 %−20.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-17.76 %+8.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-24.30 %−38.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Gem Aromatics Limited management guidance track record on Inve: 15 targets tracked across analysed earnings calls (1 achieved, 2 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Phase-II Dahej Plant CommissioningCommence on November 30th
Call transcript, Q2 FY26 · 14 Nov 2025		Q2 FY26Q1 FY27:No new updates. The plant is operational as of Q4 FY26. The promise remains achieved with a slight delay.
Call transcript, Q1 FY27 · 14 Aug 2026		Achieved*
BHA Production StartFast-tracked to start in FY27 (from FY28)
Call transcript, Q2 FY26 · 14 Nov 2025		Q2 FY26Q1 FY27:No mention of BHA production timelines for the third consecutive quarter.
Call transcript, Q1 FY27 · 14 Aug 2026		Ghosted
Company Level Revenue₹1,050-1,100 crores by FY28
Call transcript, Q2 FY26 · 14 Nov 2025		Q2 FY26Q1 FY27:The accelerated FY27 target of ₹1,100 crores is now at significant risk. Q1 FY27 revenue was only ₹99 crores, and management narrative has shifted to framing FY27 as a 'ramp-up year', implicitly pushing significant growth to FY28.
Call transcript, Q1 FY27 · 14 Aug 2026		At Risk

Source: Inve Guidance Tracker for Gem Aromatics Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Gem Aromatics Limited's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹137.95 +0.97% · +₹1.32

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −39.5% 1Y

₹140₹160₹180₹200₹220₹240Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 27 Jan 2026Q4 FY26 — 22 May 2026Q1 FY27 — 14 Aug 2026

1Y: ₹227.88 on 24 Oct 2025 → ₹137.95. High ₹234.16 (28 Oct 2025), low ₹134.63 (10 Dec 2025).

Previous close
₹136.63
Market cap
₹728 Cr
52-week range
₹134.63 – ₹234.16
One year
−39.04%
Price to earnings (FY ending Mar 2026)
728.00×
Return on equity (TTM to Jun 2026)
-3.94%

Overview

Symbol
NSE:GEMAROMA
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What Gem Aromatics Limited does

Based on the company's own presentations, annual report and earnings calls.

Gem Aromatics manufactures essential oils, aroma chemicals and value-added derivatives across Mint & Mint Derivatives, Clove & Clove Derivatives, Phenol Derivatives, Citral Chemistry and other natural/synthetic ingredients such as Eucalyptus and Lemongrass oil. Products feed into Oral Care, Cosmetics, Nutraceuticals, Pharmaceuticals, Wellness & Pain Management and Personal Care applications. Manufacturing spans three facilities (Silvassa, Budaun and the newer Dahej greenfield site), with output sold to domestic and international customers across 20 countries.

Segments

  • Mint & Mint Derivatives
  • Clove & Clove Derivatives
  • Phenol Derivatives
  • Citral Chemistry
  • Other Synthetic & Natural Ingredients
Manufacturing facilities
3 (Silvassa, Budaun, Dahej)
Total installed capacity
16,171 MTPA
Product categories
80+
Countries served
20
Domestic customers
225
Global customers
44
Founded 1997Headquarters Mumbai, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−4.4%
14 Aug
Q4 FY26
−1.8%
22 May
Q3 FY26
+0.7%
27 Jan
Q2 FY26
−5.6%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Gem Aromatics Limited

Free account: one company. Everything above stays public.

Write why you follow Gem Aromatics Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse Gem Aromatics Limited

Guides on how to read this kind of business and the numbers that matter.